CUREVAC NV (CVAC) - Price, trends, fundamentals and chart - Passport to Wall Street

CUREVAC NV (NASDAQ: CVAC)

Overview

current price

$2.59

$2.59

change

-0.25 | -8.80%

-0.25 | -8.80%

Yesterday's Close

2.84

open

2.71

volume

0.90 M

30d. avg volume.

0.64 M

1 day

2.56 - 2.76

52 weeks

2.22 - 5.28

p/e

0.00

beta

2.4817

market cap

0.64 B

dividend yield

0.00%

Industry

-

News and Commentary

Deadly Bird Flu Strain Detected In Nevada Man: 4 Stocks To Watch A Nevada dairy worker has screened positive for the D1.1 strain of bird flu associated with a Louisiana man's death in January, according to a CNN report. The Centers for Disease...

Bird Flu Update: First Commercial Case In Georgia, Moderna Receives $590 Million To Develop Vaccine According to the latest data from the Centers for Disease Control and Prevention, the current bird flu outbreak has caused 67 human cases of bird flu in the U.S. and one death as...

Bird Flu Raising Red Flags Among Health Officials, CDC Urges Faster Testing The CDC issued a health advisory Thursday recommending that hospitalized patients who have tested positive for influenza be tested for the bird flu virus within 24 hours.

Bird Flu Sparks Vaccine Stock Surge: ETFs To Watch As H5N1 Outbreak Intensifies The U.S. reported its first human death from the H5 bird flu strain this week, causing a spike in vaccine developer stocks Moderna

US Records First Human Bird Flu Death, High Levels Of Respiratory Illnesses: Vaccine Stocks Rally The Louisiana Department of Health on Monday reported the first human death in the U.S. related to the H5N1 bird flu virus. The CDC is also reporting high levels of acute respira...

GSK Buys Full Rights To Investigational Covid-19 And Influenza Vaccines From CureVac For Around $1.5... Wednesday, GSK plc (GSK...

Market Update: Stocks Climb Higher Despite More Hawkish Fedspeak Stocks rose on Tuesday, even as Federal Reserve Chair Jerome Powell delivered hawkish remarks on inflation at an event hosted by Sweden's central bank, as market participants add...

CureVac Vaccine Disappoints in Preliminary Efficacy Analysis German biotech CureVac (CVAC

GSK, CureVac Strike $180 Million Agreement to Develop Next-Gen COVID Vaccine British pharmaceutical giant GlaxoSmithKline (...

KE Holdings Raises Over $2 Billion in Public Debut The initial public offering (IPO) market is keeping a steady pace as it heads into mid-August, with four businesses and six special purpose acquisition companies (SPAC) debuting...

StockTwits

StockTwits